This June 2026 notification signals a maturing pharmacovigilance framework. For stakeholders from large-scale manufacturers and CMOs to frontline healthcare providers, the message is clear: scientific justification is the only path to market survival. This article breaks down the ban and explores the strategic shifts necessary for industry compliance.

At Walter Healthcare, we recognize that a tablet is no longer just a carrier for an active pharmaceutical ingredient (API); it is a highly engineered vehicle designed to navigate the complex physiological environment of the gastrointestinal tract, optimize bioavailability, and ensure absolute stability.

Key global regulators such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO) are constantly updating their rules. This is a direct response to the increasing complexity of new therapies and global supply chains. Their goal is to ensure innovation never comes at the cost of patient safety or product quality.

The blog is the final segment of our nutraceutical playbook, highlighting brand building in Nutraceuticals, role of CDMOs in brand success, and why choose Walter as your partner.

It provides essential coverage for a wide range of conditions, from respiratory and skin infections to various mixed bacterial ailments across all age groups, particularly when single-agent antibiotics fail. The power of this formulation lies in its strategic, dual-action mechanism. Amoxycillin offers potent, broad-spectrum bactericidal activity. Simultaneously, Clavulanic Acid acts as a guardian, breaking down the resistance mechanisms that bacteria use to neutralize the a

The India-UK Free Trade Agreement unlocks zero-duty access and faster approvals for Indian pharma exports, paving the way for deeper...